J. Dekernion

R. Figlin, A. Belldegrun, D. Wallach, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

The effects of interleukin-6 on tumor-infiltrating lymphocytes derived from human renal cell cancer.

A. Belldegrun, J. Dekernion, T. Lee, 1991, The Journal of urology.

TREATMENT OF METASTATIC RENAL CELL CARCINOMA WITH CD8( +) SELECTED TUMOR INFILTRATING LYMPHOCYTES FROM PRIMARY TUMOR NEPHRECTOMY, INTERLEUKIN-2 AND CYTOKINE-PRIMED OR

R. Figlin, A. Belldegrun, C. Tso, 1997 .

Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma.

R. Figlin, A. Belldegrun, C. Tso, 2000, Journal of immunotherapy.

Current management of renal cell carcinoma

R. Figlin, A. Belldegrun, M. Sokoloff, 1996, CA: a cancer journal for clinicians.

Decreased retinoid X receptor-alpha protein expression in basal cells occurs in the early stage of human prostate cancer development.

J. Rao, C. Cordon-Cardo, V. Reuter, 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

The natural history and clinical features of renal carcinoma.

J. Dekernion, A. Ritchie, 1987, Seminars in nephrology.

Treatment with finasteride following radical prostatectomy for prostate cancer.

G. Andriole, D. Kadmon, M. Soloway, 1995, Urology.

Adjuvant therapy for genitourinary cancer.

E. Messing, J. Dekernion, 1981, The Surgical clinics of North America.

In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin‐2 and/or interferon‐alpha gene transfer

R. Figlin, A. Belldegrun, C. Sawyers, 1994, Cancer.

The Role of Combination Biologic Therapy in the Immunotherapeutic Approach to the Treatment of Renal Cell Carcinoma

R. Figlin, A. Belldegrun, J. Dekernion, 1992 .

Spontaneous regression of liver metastasis from renal carcinoma.

L. Layfield, J. Dekernion, A. Ritchie, 1988, The Journal of urology.

The natural history of metastatic renal cell carcinoma: a computer analysis.

R. B. Smith, J. Dekernion, K. Ramming, 1978, The Journal of urology.

Chemotherapy programs of the National Prostatic Cancer Project (NPCP).

S. Loening, G. Murphy, M. Soloway, 1980, Cancer.

Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy.

R. Figlin, A. Belldegrun, A. Zisman, 2003, The Journal of urology.

Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.

M. Roth, R. Figlin, C. Tso, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Immune cytolysis of human renal carcinoma mediated by xenogeneic immune ribonucleic acid.

J. Dekernion, K. Ramming, P. Brower, 1976, The Journal of urology.

Treatment of advanced renal cell carcinoma--traditional methods and innovative approaches.

J. Dekernion, Jean B. deKernion, 1983, The Journal of urology.

Immune RNA Therapy for Renal Cell Carcinoma: Survival and Immunologic Monitoring

J. Dekernion, K. Ramming, 1977, Annals of surgery.

The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma

R. Figlin, A. Belldegrun, M. Gnant, 2005, Journal of Cancer Research and Clinical Oncology.

Autologous Tumor-Specific Cytotoxicity of Tumor-Infiltrating Lymphocytes Derived from Human Renal Cell Carcinoma

A. Belldegrun, C. Tso, J. Dekernion, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

The effects of granulocyte-macrophage colony-stimulating factor on tumour-infiltrating lymphocytes from renal cell carcinoma.

R. Figlin, A. Belldegrun, G. Steger, 1995, British Journal of Cancer.

Long-term effects of finasteride on prostate tissue composition.

A. Partin, J. Epstein, J. Dekernion, 1999, Urology.

Editorial: Perspectives on the Problem of Prostate Cancer

M. Litwin, J. Dekernion, 1994 .

Computer-generated graphical presentations: use of multimedia to enhance communication.

D. Penson, J. Dekernion, J. Maller, 1997, Urology.

Metastatic renal cell cancer: interleukin-2 toxicity induced by contrast agent injection.

R. Figlin, A. Belldegrun, J. Dekernion, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.

R. Figlin, A. Belldegrun, J. Czernin, 1994, Clinical immunology and immunopathology.

Immunotherapy for advanced renal cell cancer: the role of radical nephrectomy.

R. Figlin, A. Belldegrun, B. Bochner, 1990, European urology.

Treatment of advanced renal cell carcinoma.

J. Dekernion, A. Lindner, 1982, Progress in clinical and biological research.

Regulatory effects of interleukin-4 on tumor-infiltrating lymphocytes derived from human renal cell carcinoma.

A. Belldegrun, B. Bochner, J. Dekernion, 1992, The Journal of surgical research.

Urinary retention after orthotopic neobladder substitution in females.

D. Finley, J. Dekernion, U. Lee, 2011, The Journal of urology.

The value of computerized tomography scan and magnetic resonance imaging in staging prostatic carcinoma: comparison with the clinical and histological staging.

J. Dekernion, Z. Barbaric, E. Mukamel, 1986, The Journal of urology.

Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer.

C. Tso, M. Sokoloff, J. Dekernion, 1995, Human gene therapy.

Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology.

R. Figlin, A. Belldegrun, A. Zisman, 2001, Human gene therapy.

Carcinoma of the penis

J. Dekernion, L. Persky, P. Tynberg, 1973 .

Human reproductive tissues contain thyrotropin releasing hormone (TRH) and TRH-homologous peptides.

J. Hershman, J. Dekernion, A. Pekary, 1983, Journal of andrology.

Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.

A. Partin, J. Dekernion, F. Dorey, 1997, The Journal of urology.

Work in progress: transcatheter embolization of renal cell carcinoma with radioactive infarct particles.

J. Dekernion, J. Sullivan, E. Lang, 1983, Radiology.

The treatment of renal cell carcinoma with human leukocyte alpha-interferon.

R. Figlin, R. B. Smith, J. Dekernion, 1983, The Journal of urology.

Bridging the gap: Health disparity research initiatives through the department of defense (DOD) congressionally directed medical research programs (CDMRP) prostate cancer research program (PCRP)

Jeffrey R. Smith, M. Roach, T. Carey, 2005 .

Early versus delayed lymph-node dissection versus no lymph-node dissection in carcinoma of the penis.

J. Dekernion, E. Mukamel, 1987, The Urologic clinics of North America.

Result of treatment of patients with stage D1 prostatic carcinoma.

R. B. Smith, J. Dekernion, J. Kaufman, 1985, Urology.

Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.

R. Figlin, J. Dekernion, L. Itri, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alum irrigation for severe bladder hemorrhage.

J. Dekernion, E. Mukamel, A. Lupu, 1986, The Journal of urology.

Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.

A. Partin, J. Epstein, R. Veltri, 2000, The Journal of urology.

Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma.

R. Figlin, A. Belldegrun, A. Zisman, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Subepithelial hematoma of the renal pelvis (Antopol-Goldman lesion): a case report and review of the literature.

J. Dekernion, J. Waisman, S. Levitt, 1984, The Journal of urology.

Acute scrotal pain and swelling in children: a surgical emergency.

R. Flanigan, J. Dekernion, L. Persky, 1981, Urology.

Clinical management of foreign bodies of the genitourinary tract.

J. Dekernion, A. van Ophoven, 2000, The Journal of urology.

Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia.

A. Partin, J. Dekernion, F. Dorey, 1996, The Journal of urology.

Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of prostate.

R. B. Smith, J. Dekernion, A. Stein, 1992, Urology.

Adjuvant radiotherapy in patients post-radical prostatectomy with tumor extending through capsule or positive seminal vesicles.

R. B. Smith, J. Dekernion, F. Dorey, 1992, Urology.

Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder.

D. Lamm, M. Hanna, J. Dekernion, 1989, Progress in clinical and biological research.

The creation and care of enterocutaneous stomas

W. Barker, E. Fonkalsrud, J. Benfield, 1975 .

Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer.

R. B. Smith, J. Dekernion, F. Dorey, 1992, The Journal of urology.

Invasive giant condylomata acuminata: a case report.

L. Layfield, H. Gritsch, J. Dekernion, 1989, The Journal of urology.

Carcinoma of the penis

J. Dekernion, L. Persky, 1976, CA: a cancer journal for clinicians.

The Kock pouch as a urinary reservoir. Pitfalls and perspectives.

J. Dekernion, J. Kaufman, L. Denbesten, 1985, American journal of surgery.

A bladder tumor model response to immunotherapy.

J. Dekernion, K. Ramming, K. Fraser, 1978, National Cancer Institute monograph.

The detection and clinical significance of antibodies to tumor-associated antigens in patients with renal cell carcinoma.

R. Gupta, J. Dekernion, K. Ramming, 1979, The Journal of urology.

Expression of cellular oncogenes in human malignancies.

I. Verma, D. Slamon, J. Dekernion, 1984, Science.

The Diagnosis and Treatment of Renal Cell Carcinoma

J. Dekernion, D. Berry, JEAN B. DeKERNION, 1980, Cancer.

Preliminary results on the use of the humoral immune response as a serum marker in patients with bladder tumors

U. Studer, J. Dekernion, L. Lovrekovich, 2004, Urological Research.

Serum alpha-fetoprotein and human chorionic gonadotropin in patients with seminoma.

P. Scardino, W. Catalona, P. Lange, 1980, The Journal of urology.

Treatment of advanced seminoma with pre-radiation chemotherapy.

E. Crawford, R. B. Smith, J. Dekernion, 1983, The Journal of urology.

Chemotherapy of hormonally unresponsive prostatic carcinoma.

J. Dekernion, A. Lindner, 1984, Urologic clinics of North America.

Primary small cell carcinoma of the augmented urinary bladder.

J. Dekernion, K. Lewin, S. Raz, 1992, British journal of urology.

Serum-free medium for the in vitro growth of normal and malignant urinary bladder epithelial cells.

E. Messing, J. Fahey, J. Dekernion, 1982, Cancer research.

Detection of onco-fetal bladder antigen in urine of patients with transitional cell carcinoma.

J. Fahey, L. M. Stock, J. Dekernion, 1987, The Journal of urology.

Murine hybridoma antibodies against human transitional carcinoma-associated antigens.

E. Messing, J. Fahey, K. Whitmore, 1984, The Journal of urology.

Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.

R. Figlin, A. Belldegrun, C. Tso, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Cell surface blood group antigens in prostatic carcinoma.

J. Dekernion, P. Walker, J. C. Pramberg, 1984, American journal of clinical pathology.

Morphometry of the prostate: I. Distribution of tissue components in hyperplastic glands.

B. Treiger, J. Dekernion, F. Dorey, 1994, Urology.

Management of advanced testicular seminoma.

D. Skinner, R. B. Smith, J. Dekernion, 1979, The Journal of urology.

The response of metastatic retroperitoneal seminoma to chemotherapy.

J. Dekernion, A. Lupu, 1977, The Journal of urology.

Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves.

J. Richie, L. Kavoussi, P. Scardino, 1994, The Journal of urology.

The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy.

R. B. Smith, J. Dekernion, F. Dorey, 1994, The Journal of urology.

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Louis R Kavoussi, William J Catalona, J. Richie, 1994, The Journal of urology.

Interleukin-6 and renal cell cancer: Production, regulation, and growth effects

A. Belldegrun, B. Bochner, C. Tso, 2005, Cancer Immunology, Immunotherapy.

Diagnosis and treatment of prostate cancer.

J. Dekernion, J Naitoh, R L Zeiner, 1998, American family physician.

Quantitative Polymerase Chain Reaction Does not Improve Preoperative Prostate Cancer Staging: A Clinicopathological Molecular Analysis of 121 Patients

R. Figlin, A. Belldegrun, C. Tso, 1998 .

Prognostic factors in metastatic renal carcinoma.

J. Dekernion, J. Maldazys, 1986, The Journal of urology.

The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.

R. B. Smith, J. Dekernion, J. Kaufman, 1985, The Journal of urology.

Immunotherapy of human malignancies with immune RNA

J. Dekernion, K. Ramming, Y. Pilch, 1977, World Journal of Surgery.

Immunotherapy of cancer with "immune" RNA: current status.

J. Dekernion, Y. Pilch, 1974, Seminars in oncology.

Improved prognostication of renal cell carcinoma using an integrated staging system.

R. Figlin, A. Belldegrun, A. Zisman, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of late complications of ileal conduit.

E. Fraley, J. Dekernion, D. Paulson, 1969, The Journal of urology.

The natural history of renal cell carcinoma.

A. Stenzl, J. Dekernion, Arnulf Stenzl, 1989, Seminars in urology.

Low p27 expression predicts poor disease-free survival in patients with prostate cancer.

M. Loda, M. Murphy, J. Dekernion, 1998, The Journal of urology.

Acute effects of orally administered levamisole on random monocyte motility and chemotaxis in man.

J. Fahey, S. Nathanson, J. Dekernion, 1978, Journal of the National Cancer Institute.

Selection of initial therapy for renal cell carcinoma

J. Dekernion, E. Mukamel, 1987, Cancer.

Interferon-α Primed Tumor-Infiltrating Lymphocytes Combined with Interleukin-2 and Interferon-α as Therapy for Metastatic Renal Cell Carcinoma

R. Figlin, A. Belldegrun, C. Tso, 1993 .

Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.

R. Figlin, J. Dekernion, G. Sarna, 1985, Cancer treatment reports.

Renal cell carcinoma: recent progress and future directions.

R. Figlin, A. Belldegrun, P. Mulders, 1997, Cancer research.

Pitfalls in preoperative staging in prostate cancer.

J. Dekernion, E. Mukamel, J. Hanna, 1987, Urology.

Cancer‐specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989‐2005)

A. Belldegrun, B. Shuch, A. Pantuck, 2008, Cancer.

TRANSITIONAL-CELL CARCINOMA*

M. Soloway, J. Dekernion, 1974 .

Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.

A. Belldegrun, E. Landaw, J. Dekernion, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of metastatic disease in men with biochemical failure following radical prostatectomy.

S. Freedland, W. Aronson, J. Dekernion, 2004, The Journal of urology.

In Vivo Imaging of Intraprostatic-Specific Gene Transcription by PET

N. Satyamurthy, D. Stout, F. Pouliot, 2011, The Journal of Nuclear Medicine.

Preliminary studies of specific immunotherapy of cancer with immune RNA

J. Dekernion, K. Ramming, Y. Pilch, 1977 .

Three-dimensional ultrasound device for rapid determination of bladder volume.

J. Dekernion, F. Dorey, L. Marks, 1997, Urology.

Risk of urinary incontinence following radical prostatectomy.

R. B. Smith, J. Dekernion, A. Lindner, 1983, The Journal of urology.

Early post-operative morbidity of total prostatectomy.

J. Dekernion, K. James, A. Ritchie, 1989, British journal of urology.

Bilateral renal cell carcinoma and renal cell carcinoma in the solitary kidney.

D. Skinner, R. B. Smith, J. Dekernion, 1984, The Journal of urology.

Mathematical model to predict individual survival for patients with renal cell carcinoma.

R. Figlin, A. Belldegrun, A. Zisman, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

COMPARISON OF DIGITAL RECTAL EXAMINATION AND SERUM PROSTATE SPECIFIC ANTIGEN IN THE EARLY DETECTION OF PROSTATE CANCER: RESULTS OF A MULTICENTER CLINICAL TRIAL OF 6,630 MEN

J. Richie, L. Kavoussi, P. Scardino, 1994, The Journal of urology.

Prostatic specific antigen related to clinical status 1 to 14 years after radical retropubic prostatectomy.

J. Dekernion, F. Dorey, A. Stein, 1991, British journal of urology.

Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy.

A. Stenzl, J. Dekernion, F. Dorey, 1990, The Journal of urology.

Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.

R. Figlin, A. Belldegrun, C. Tso, 1997, The Journal of urology.

Immunotherapy for renal cell carcinoma.

R. Figlin, A. Belldegrun, J. Dekernion, 1992, Seminars in urology.

Transcatheter embolization of advanced renal cell carcinoma with radioactive seeds.

J. Dekernion, E. Lang, 1981, The Journal of urology.

Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria.

R. Figlin, A. Belldegrun, K. Tsui, 2000, The Journal of urology.

Role of lymphadenectomy for patients undergoing radical nephrectomy for renal cell carcinoma.

S. Freedland, J. Dekernion, 2003, Reviews in urology.

Treatment of skeletal metastases from urologic malignancies.

J. Dekernion, T. Grant, 1978, Urology.

Cost effective analysis of prenephrectomy radioisotope scans in renal cell carcinoma.

J. Dekernion, A. Lindner, D. Goldman, 1983, Urology.

Patch grafting the renal pelvis and ureteropelvic junction

P. Royce, J. Dekernion, P. Zimmern, 2004, Urological Research.

Levamisole in the treatment of non-invasive and invasive bladder cancer: a preliminary report.

D. Skinner, R. B. Smith, B. Baron, 1978, The Journal of urology.

CL1-GFP: an androgen independent metastatic tumor model for prostate cancer.

A. Pantuck, A. Zisman, C. Tso, 2000, The Journal of urology.

Na,K-adenosine triphosphatase alpha1-subunit predicts survival of renal clear cell carcinoma.

William S. Ball, S. Horvath, D. Seligson, 2008, The Journal of urology.

Controversies in ilioinguinal lymphadenectomy for cancer of the penis.

J. Dekernion, A. Abi-Aad, 1992, The Urologic clinics of North America.

Urologic Applications of Regional Chemotherapy

J. Dekernion, J. Maldazys, 1986 .

Chemotherapy of experimental transitional-cell carcinoma.

M. Soloway, J. Dekernion, L. Persky, 1974, Urology.

Malignant melanoma metastatic to the bladder. Regression following intratumor injection of BCG vaccine.

M. Silverstein, D. Morton, J. Dekernion, 1974, JAMA.

Ultrasound-based combination therapy: potential in urologic cancer

A. Belldegrun, A. Pantuck, B. Shuch, 2011, Expert review of anticancer therapy.

Transitional cell carcinoma of bladder in first four decades of life.

J. Dekernion, A. Lindner, R. Cherrie, 1982, Urology.

Use of fine needle aspiration for detection of stage A prostatic carcinoma before transurethral resection of the prostate: a clinical trial.

L. Layfield, R. B. Smith, J. Dekernion, 1987, The Journal of urology.

The chemotherapy of advanced bladder carcinoma.

J. Dekernion, 1977, Cancer research.

Effect of chemotherapeutic agents on bladder cancer: a new animal model.

M. Soloway, J. Dekernion, L. Persky, 1973, Surgical forum.

Carcinoma of the penis

J. Dekernion, L. Persky, 1976, CA: a cancer journal for clinicians.

Antibodies to cultured tumor cells detected in sera of renal cell carcinoma patients by a quantitative avidin-biotin method.

D. Chopin, U. Studer, J. Dekernion, 1986, The Journal of urology.

Dominant B cell epitope from NY‐ESO‐1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential biomarker

A. Belldegrun, A. Pantuck, S. Dubinett, 2005, International journal of cancer.

Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial.

J. Richie, P. Scardino, W. Catalona, 2000, Urology.

Open Radical Nephrectomy for Localized Renal Cell Carcinoma

J. Dekernion, S. Vemulapalli, 2008 .

Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system.

A. Belldegrun, K. Tsui, R. B. Smith, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphadenectomy for renal cell carcinoma. Therapeutic implications.

J. Dekernion, 1980, The Urologic clinics of North America.

Surgical treatment of Peyronie's disease: a new approach.

J. Dekernion, J. Kaufman, S. Raz, 1976 .

Preoperative endoscopic diagnosis of fibroepithelial polyp of the renal pelvis: a case report and review of the literature.

L. Layfield, J. Dekernion, M. Macfarlane, 1991, The Journal of urology.

Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.

R. Figlin, A. Belldegrun, J. Dekernion, 1997, The cancer journal from Scientific American.

Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.

R. Figlin, A. Belldegrun, C. Tso, 1993, The Journal of urology.

Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer.

Louis R Kavoussi, William J Catalona, J. Richie, 1994, The Journal of urology.

Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination.

Louis R Kavoussi, William J Catalona, J. Richie, 1993, Urology.

Editorial Comment: Laparoscopic Nephrectomy for Renal-Cell Carcinoma: The Current Situation

P. Schulam, J. Dekernion, 2001 .

Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study.

J. Richie, A. Novick, D. Miller, 1995, The Journal of urology.

Tensor fascia lata myocutaneous flap for coverage of skin defect after radical groin dissection for metastatic penile carcinoma.

J. Dekernion, R. A. Airhart, E. O. Guillermo, 1982, The Journal of urology.

Unusual case of urethral carcinoma.

J. Dekernion, J. Roth, J. R. Angel, 1981, Urology.

PROSTATE TISSUE COMPOSITION AND RESPONSE TO FINASTERIDE IN MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA

A. Partin, J. Dekernion, F. Dorey, 1998 .

Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen.

J. Dekernion, F. Dorey, F Dorey, 1997, The Journal of urology.

Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.

J. Richie, L. Kavoussi, W. Catalona, 1994, The Journal of urology.

The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate

P. Scardino, S. Loening, G. Murphy, 1983, Journal of surgical oncology.

Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer.

A. Belldegrun, J. Dekernion, A. Belldegrun, 1993, The Journal of urology.

Clinical Urology: Letter to the EditorIn Reply: Re: Selection of Optimal Prostate Specific Antigen Cutoffs for Early Detection of Prostate Cancer: Receiver Operating Characteristic Curves

J. Richie, L. Kavoussi, P. Scardino, 1996 .

Conservative treatment of diffuse carcinoma in situ of the bladder with repeated courses of intravesical therapy.

J. Dekernion, E. Mukamel, 1989, British journal of urology.

Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.

S. Freedland, W. Aronson, J. Dekernion, 2002, The Journal of urology.

Local response and long-term results of preoperative M-VAC regimen in regionally advanced transitional cell carcinoma of the bladder.

R. Figlin, A. Stenzl, J. Dekernion, 1993, European journal of cancer.

Cytological grading of prostatic aspiration biopsy: a comparison with the Gleason grading system.

B. Ljung, B. Glasgow, L. Layfield, 1987, Journal of Urology.

The significance of atypia in fine needle aspiration cytology of the prostate.

L. Layfield, J. Dekernion, A. Ritchie, 1988, Journal of Urology.

Routine or Ultrasound-Guided Biopsy for a Benign Prostatic Lesion

A. Stenzl, L. Layfield, J. Dekernion, 1991 .

Antitumor effect of heat-killed Aspergillus fumigatus mycelium in a mouse model

J. Dekernion, L. Lovrekovich, 2004, Cancer Immunology, Immunotherapy.

Dietary boron intake and reduced risk of prostate cancer

Zuo-Feng Zhang, J. Dekernion, J. Marshall, 2002 .

Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy

M. Steinberg, C. King, R. Reiter, 2015, American journal of clinical oncology.

Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound.

J. Dekernion, M. Macfarlane, A. Abi-Aad, 1992, The Journal of urology.

Cost-effective analysis of pre-cystectomy radioisotope scans.

J. Dekernion, A. Lindner, Jean B. deKernion, 1982, The Journal of urology.

Surgical treatment of Peyronie's disease: a new approach

J. Dekernion, J. Kaufman, S. Raz, 1978, The Journal of urology.

Adjuvant endocrine therapy after radical prostatectomy for stage D1 prostate carcinoma.

J. Dekernion, A. Stein, 1990, Seminars in urology.

Significance of histological prognostic indicators in patients with carcinoma of the prostate.

J. Dekernion, F. Dorey, E. Mukamel, 1990, British journal of urology.

Cost-efficient radical prostatectomy with a clinical care path.

M. Litwin, R. B. Smith, J. Dekernion, 1996, The Journal of urology.

Immunotherapy for malignant lesions in man using immunogenic ribonucleic acid.

D. Skinner, J. Dekernion, K. Ramming, 1975, American journal of surgery.

Intracellular localization of anti-tumor immune RNA.

J. Dekernion, D. Kern, Y. Pilch, 1976, Cellular immunology.

Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.

A. Belldegrun, S. Barsky, C. Tso, 1993, Journal of the National Cancer Institute.

In vitro modulation of tumor progression‐associated properties of hormone refractory prostate carcinoma cell lines by cytokines

A. Belldegrun, S. Taneja, C. Tso, 1996, Cancer.

Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome.

R. Figlin, A. Belldegrun, A. Zisman, 2001, The Journal of urology.

The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma.

R. Figlin, A. Belldegrun, J. Dekernion, 1991, Seminars in Oncology.

Blood loss and the need for transfusion in patients who undergo partial or radical nephrectomy for renal cell carcinoma.

A. Belldegrun, K. Tsui, R. B. Smith, 2000, The Journal of urology.

Advanced renal cell carcinoma: treatment with xenogeneic immune ribonucleic acid and appropriate surgical resection.

D. Skinner, J. Dekernion, K. Ramming, 1976, The Journal of urology.

Metastatic carcinoma to penis: when is total penectomy indicated?

J. Dekernion, E. Mukamel, Robert B. Smith, 1987, Urology.

Immunotherapy in Renal Cell Carcinoma; Cellular Immunotherapy

R. Figlin, A. Belldegrun, S. Taneja, 1996 .

A model for a bladder replacement plasty by an ileal reservoir — An experimental study in dogs

U. Studer, J. Dekernion, P. Zimmern, 2004, Urological Research.

Immunological therapy in urological malignancy: Novel combination strategies

A. Belldegrun, A. Pantuck, B. Shuch, 2011, International journal of urology : official journal of the Japanese Urological Association.

The response of the stilbestrol‐induced renal tumor to chemotherapeutic agents

Martin L. Resnick, J. Dekernion, L. Persky, 1973, Journal of surgical oncology.

Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.

R. Figlin, A. Belldegrun, C. Tso, 1997, The Journal of urology.

The effect of bacillus Calmette-Guerin on the urinary system of pigs.

L. Layfield, J. Dekernion, R. Hawkins, 1987, The Journal of urology.

Quantitative measurements of humoral immune response in mice to a FANFT induced bladder tumor

U. Studer, J. Dekernion, H. Lovrekovich, 2004, Urological Research.

Intravesical bacillus Calmette-Guérin and second primary malignancies.

D. Lamm, S. Brosman, M. Hanna, 1989, Urology.

The influence of dactinomycin on compensatory renal hypertrophy.

J. Dekernion, L. Persky, P. Tynberg, 1973, The Journal of surgical research.

Modulation of tumor-infiltrating lymphocytes derived from human renal cell carcinoma by interleukin-4.

A. Belldegrun, C. Tso, J. Dekernion, 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

The incidence and significance of seminal vesicle invasion in patients with adenocarcinoma of the prostate

D. Skinner, J. Dekernion, E. Mukamel, 1987, Cancer.

Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma.

J. Richie, P. Scardino, W. Catalona, 1995, British journal of urology.